Bli medlem
Bli medlem

Du är här

2016-07-25

Medigene AG: Medigene expands TCR platform technology with US patent for method for identification of CD4+ T cell antigens

Medigene AG / Medigene expands TCR platform technology with US patent for
method foridentification of CD4+ T cell antigens . Processed and transmitted
by NASDAQ OMX Corporate Solutions.The issuer is solely responsible for the
content of this announcement.
* Patent covers a rapid and efficient method for identifying tumor-specific
antigens
* Expected to facilitate the use of neoantigens in personalized T-cell
therapies
* Provides a new source for potential TCR candidates

Martinsried/Munich, 25 July 2016.
Medigene AG(MDG1, Frankfurt, Prime Standard), a clinical stage immune-oncology
company focusing on the development of T cell immuno-therapies for the
treatment of cancer, announces the grant of US patent US9,341,617B2. The
patent, with an expected life-span until 2030, claims a method for the
identification of antigens recognized by CD4+ T cells, including tumor
infiltrating CD4+ T cells.

This patent expands Medigene's T-cell receptor (TCR) platform technology with
an additional fast and efficient method for the direct identification of
antigens and respective epitopes recognized by CD4+ tumor infiltrating
lymphocytes and opens the way to identify immune relevant patient-specific
neoantigens. Rapid definition of epitopes recognized by CD4+ T helper cells
for generation of tumor vaccines also becomes potentially possible.

Prof. Dolores Schendel, CEO and CSO of Medigene,
explains: "This newly patented method provides the company with a potential
additional source for new TCR candidates and also allows us to identify
patient-specific neoantigens seen by CD4+ T cells. While CD4+ tumor
infiltrating T cells have been known in the past, finding the antigens for
which these T cells are specific was very time-consuming and complex. With
the covered method we are now able to overcome these problems and it helps us
to provide expanded options for adoptive T-cell therapies with transgenic
T-cell receptors."

Medigene holds an exclusive license to the patent that was issued to Helmholtz
Zentrum München (German Research Center for Environmental Health). Patents
within the same patent family have already been granted in Europe, Australia
and Canada.

About Medigene's TCR patent portfolio:
Medigene's IP-portfolio relating to the TCR platform comprises 4 patent
families covering methods for the identification of tumor-antigen specific T
cell receptors and T cell receptors targeting specific tumor antigens. The 4
patent families in turn comprise 47 granted patents (including validations in
Europe) and 14 pending applications. In addition, Medigene is constantly
expanding its IP portfolio by filing applications for new methods and newly
identified T-cell receptors specific for various tumor-antigens.

About CD4
+
T cells in tumor biology:
Recent advances in cellular immunotherapy show that cancer cells can be
efficiently eliminated by adoptive transfer of modified patient T cells. The
main effector functions can be provided by genetically engineered lymphocytes
expressing T-cell receptors isolated from tumor antigen-specific cytotoxic
CD8+ lymphocytes, which recognize tumor-associated antigens presented on HLA
class I molecules. Nevertheless, CD4+ T lymphocytes play a critical role for
efficient and sustained cytotoxic CD8+ T cell responses and memory function.
Multifunctional CD4+ T cells are essential to activate, control and maintain
immune responses. CD4+ T cells recognize antigens presented on HLA class II
molecules; thereby HLA class II tumor antigen-positive cells may be
efficiently eliminated also by direct CD4+ cytotoxic mechanisms. It was
demonstrated that adoptive transfer of tumor antigen-specific CD4+ T cells
alone can lead to substantial regression of epithelial tumors (Science. 2014
May 9;344(6184):641-5).

About Medigene's TCR technology:

The TCR technology aims at arming the patient's own T cells with
tumor-specific T-cell receptors. The receptor-modified T cells are then able
to detect and efficiently kill tumor cells. This immunotherapy approach
attempts to overcome the patient's tolerance towards cancer cells and
tumor-induced immunosuppression by activating and modifying the patient's T
cells outside the body (ex-vivo
). A large number of specific T cells to fight the tumor is thereby made
available to patients within a short period of time.

Medigene's technology for T-cell receptor-modified T cells is one of the
company's highly innovative and complementary immunotherapy platforms for
adoptive T-cell therapy. The TCR therapy is designed to treat patients with
high tumor loads. Medigene is preparing the clinical development of its first
TCR candidates and is developing a library of recombinant T-cell receptors.
Moreover, a Good Manufacturing Practice (GMP)-compliant process for their
combination with patient-derived T cells is currently being established.
Medigene plans to commence its first own clinical TCR trials in 2017 and a
second in 2018.

Medigene AG
is a publicly listed (Frankfurt: MDG1, prime standard) biotechnology company
headquartered in Martinsried near Munich, Germany. The company is developing
highly innovative complementary treatment platforms to target various types
and stages of cancer with candidates in clinical and pre-clinical
development. Medigene concentrates on the development of personalized T
cell-based immunotherapies.

For more information, please visitwww.medigene.com

This press release contains forward-looking statements representing the
opinion of Medigene as of the date of this release. The actual results
achieved by Medigene may differ significantly from the forward-looking
statements made herein. Medigene is not bound to update any of these
forward-looking statements. Medigene
®
is a registered trademark of Medigene AG. This trademark may be owned or
licensed in select locations only.

Contact Medigene

Julia Hofmann, Dr. Robert Mayer
Tel.: +49 - 89 - 20 00 33 - 33 01
Email:investor@medigene.com

Should you no longer wish to receive any information about Medigene, please
inform us by e-mail (investor@medigene.com). We will then delete your address
from our distribution list.

press release as pdf
http://hugin.info/132073/R/2030243/755133.pdf

---------------------------------------

This announcement is distributed by NASDAQ OMX Corporate Solutions on behalf of NASDAQ OMX Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Medigene AG via Globenewswire

HUG#2030243

Författare Hugin

Tala om vad ni tycker

Tala om vad ni tycker

Ni är just nu inne på en betaversion av nya aktiespararna. Lämna gärna feedback på vad ni tycker i formuläret nedan.